GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gamida Cell Ltd (OTCPK:GMDAQ) » Definitions » Volatility

Gamida Cell (Gamida Cell) Volatility : 163.25% (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gamida Cell Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-04-29), Gamida Cell's Volatility is 163.25%.


Competitive Comparison of Gamida Cell's Volatility

For the Biotechnology subindustry, Gamida Cell's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gamida Cell's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gamida Cell's Volatility distribution charts can be found below:

* The bar in red indicates where Gamida Cell's Volatility falls into.



Gamida Cell  (OTCPK:GMDAQ) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gamida Cell  (OTCPK:GMDAQ) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Gamida Cell Volatility Related Terms

Thank you for viewing the detailed overview of Gamida Cell's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Gamida Cell (Gamida Cell) Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Executives
Jeremy Blank director 6446 DREXEL AVENUE, LOS ANGELES CA 90048
Mary Theresa Coelho officer: Chief Financial Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Ronit Simantov officer: CMO & Chief Scientific Officer 1988 CHAPEL STREET, NEW HAVEN CT 06515
Abigail L. Jenkins director, officer: President and CEO C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116
Stephen T Wills director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ivan M. Borrello director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Anat Cohen-dayag director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Naama Halevi-davidov director C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bio Medical Investment (1997) Ltd. other: Affiliate of 10% Owner 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301
Shai Lankry officer: Chief Financial Officer C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Ai Gamida Holdings Llc other: Affiliate of 10% Owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ofer Gonen director 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Clal Biotechnology Industries Ltd. other: Affiliate of 10% Owner 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Gamida Cell (Gamida Cell) Headlines

From GuruFocus

Gamida Cell Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-07-2024

Q2 2023 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q4 2021 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q4 2022 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024